Therapeutic Development in COVID-19

被引：2

作者：

Yang, Chan ^{[1
]}

Huang, Yuan ^{[1
]}

Liu, Shuwen ^{[2
,3
,4
]}

机构：

[1] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou, Peoples R China

[2] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou, Peoples R China

[3] Southern Med Univ, Guangdong Prov Inst Nephrol, State Key Lab Organ Failure Res, Guangzhou, Peoples R China

[4] Universal Sci Educ & Res Network USERN, Network Immun Infect Malignancy & Autoimmun NIIMA, Guangzhou, Peoples R China

来源：

CORONAVIRUS DISEASE - COVID-19 | 2021年 / 1318卷

关键词：

Antiviral; COVID-19; Drugs; SARS-CoV-2; Therapy; SPIKE PROTEIN; CORONAVIRUS; VIRUS; CHLOROQUINE; SARS; LOPINAVIR/RITONAVIR; HYDROXYCHLOROQUINE; EFFICACY; DISEASE; FAVIPIRAVIR;

D O I：

10.1007/978-3-030-63761-3_25

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Since the outbreak of coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2, the disease has spread rapidly worldwide and developed into a global pandemic, causing a significant impact on the global health system and economic development. Scientists have been racing to find effective drugs and vaccines for the treatment and prevention of COVID-19. However, due to the diversity of clinical manifestations caused by COVID-19, no standard antiviral regimen beyond supportive therapy has been established. Ongoing clinical trials are underway to evaluate the efficacy of drugs that primarily act on the viral replication cycle or enhanced immunity of patients. This chapter will summarize the currently used antiviral and adjuvant therapies in clinical practice and provide a theoretical basis for the future treatment of COVID-19.

引用

页码：435 / 448

页数：14

共 97 条

[1] Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease [J].

Agostini, Maria L. ;

Andres, Erica L. ;

Sims, Amy C. ;

Graham, Rachel L. ;

Sheahan, Timothy P. ;

Lu, Xiaotao ;

Smith, Everett Clinton ;

Case, James Brett ;

Feng, Joy Y. ;

Jordan, Robert ;

Ray, Adrian S. ;

Cihlar, Tomas ;

Siegel, Dustin ;

Mackman, Richard L. ;

Clarke, Michael O. ;

Baric, Ralph S. ;

Denison, Mark R. .

MBIO, 2018, 9 (02)

[2] Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity [J].

Aguiar, Anna C. C. ;

Murce, Erika ;

Cortopassi, Wilian A. ;

Pimentel, Andre S. ;

Almeida, Maria M. F. S. ;

Barros, Daniele C. S. ;

Guedes, Jessica S. ;

Meneghetti, Mario R. ;

Krettli, Antoniana U. .

INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE, 2018, 8 (03) :459-464

[3] Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review [J].

Alijotas-Reig, Jaume ;

Esteve-Valverde, Enrique ;

Belizna, Cristina ;

Selva-O'Callaghan, Albert ;

Pardos-Gea, Josep ;

Quintana, Angela ;

Mekinian, Arsene ;

Anunciacion-Llunell, Ariadna ;

Miro-Mur, Francesc .

AUTOIMMUNITY REVIEWS, 2020, 19 (07)

[4] Coronavirus main proteinase (3CLpro) structure:: Basis for design of anti-SARS drugs [J].

Anand, K ;

Ziebuhr, J ;

Wadhwani, P ;

Mesters, JR ;

Hilgenfeld, R .

SCIENCE, 2003, 300 (5626) :1763-1767

[5] Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus [J].

Angel Martinez, Miguel .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (05)

[6]

[Anonymous], 2020, ZHONGHUA NEI KE ZA Z

[7] Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? [J].

Antinori, Spinello ;

Bonazzetti, Cecilia ;

Gubertini, Guido ;

Capetti, Amedeo ;

Pagani, Cristina ;

Morena, Valentina ;

Rimoldi, Sara ;

Galimberti, Laura ;

Sarzi-Puttini, Piercarlo ;

Ridolfo, Anna Lisa .

AUTOIMMUNITY REVIEWS, 2020, 19 (07)

[8] Potential of heparin and nafamostat combination therapy for COVID-19 [J].

Asakura, Hidesaku ;

Ogawa, Haruhiko .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (06) :1521-1522

[9]

Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI [10.1056/NEJMoa2007764, 10.1056/NEJMc2022236]

[10] Single-chain antibodies against a plant viral RNA-dependent RNA polymerase confer virus resistance [J].

Boonrod, KJ ;

Galetzka, D ;

Nagy, PD ;

Conrad, U ;

Krczal, G .

NATURE BIOTECHNOLOGY, 2004, 22 (07) :856-862

← 1 2 3 4 5 6 7 8 9 10 →